Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations

Corrigendum Scichilone N, Spatafora M, Battaglia S, Arrigo R, Benfante A, Bellia V. J Asthma Allergy. 2013;6:11–21.On page 15, the note in the legend for Figure 3 was incorrectly listed as "The improvement is greater in the extra-fine beclomethasone-formoterol combination group than in the non-extra-fine fluticasone propionate-formoterol group". The correct sentence is "The improvement is greater in the extra-fine beclomethasone-formoterol combination group than in the non-extra-fine fluticasone propionate-salmeterol group".On page 16, there is a missing note for Figure 4. Note: Data on file. (Chiesi Farmaceutici S.p.A, 2012)Read the original article